University of Kufa obtained a patent on the SRA 737 Checkpointkinase1 inhibitor as a new targeted therapy for non-small cell lung cancer and colorectal cancer cells.
Kufa University Obtains Patent
You Might Also Like
Dr. Al-Aboudi Inaugurates Art Exhibitions in Cooperation with Iraqi Artists Syndicate & Syndicate Expresses Appreciation for Dr. Al-Aboudi Initiative to Enrich Universities’ Visual Space
University’s Master’s Dissertation on Treatment of Petroleum Wastewater
